Literature DB >> 8621227

Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma.

F Doi1, D D Chi, B B Charuworn, A J Conrad, J Russell, D L Morton, D S Hoon.   

Abstract

The beta chain of human chorionic gonadotropin (hCG) hormone is produced by fetal cells, gonadal cell tumors and several types of non-gonadal carcinoma. hCG is composed of an alpha and a beta chain, the latter of which can be used to distinguish the molecule from other related gonadotropin hormones. Detection of beta-hCG mRNA transcripts can be potentially useful as a marker to identify tumor cells. We devised a highly specific and sensitive assay to detect the atavistic expression of beta-hCG in cutaneous melanoma by RT-PCR. Twenty-four melanoma cell lines and 43 melanoma biopsies were evaluated for beta-hCG mRNA expression. An RT-PCR assay was developed to specifically distinguish beta-hCG poly-A mRNA from other related gonadotropin beta chains. This was performed by endonuclease digestion of a unique Sty 1 site in the beta chain, followed by Southern blot analysis with a beta-hCG cDNA probe. Of the 24 melanoma cell lines analyzed, 18 expressed beta-hCG mRNA. Analysis of melanoma biopsy specimens revealed beta-hCG mRNA expression in 17/25 melanoma-positive TDLN, and in only 5/15 non-lymphoid melanoma metastases. Beta-hCG mRNA expression had a 53% correlation to tyrosinase mRNA, a predominant melanoma marker. Beta-hCG mRNA was not detected in normal donor PBL and normal lymph nodes. Detection of beta-hCG mRNA expression may be a useful molecular marker to define a subset of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621227     DOI: 10.1002/(SICI)1097-0215(19960208)65:4<454::AID-IJC11>3.0.CO;2-A

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Authors:  Elizabeth Ann L Enninga; Shernan G Holtan; Douglas J Creedon; Roxana S Dronca; Wendy K Nevala; Simona Ognjanovic; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

2.  Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.

Authors:  Kaan Harmankaya; Christa Erasim; Claus Koelblinger; Ramy Ibrahim; Axel Hoos; Hubert Pehamberger; Michael Binder
Journal:  Med Oncol       Date:  2010-07-01       Impact factor: 3.064

3.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

Authors:  D D Chi; R E Merchant; R Rand; A J Conrad; D Garrison; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

4.  An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes.

Authors:  S Abdul-Rasool; S H Kidson; E Panieri; D Dent; K Pillay; G S Hanekom
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

5.  Cellular immuno-PCR. Detection of a carbohydrate tumor marker.

Authors:  Z Zhang; R F Irie; D D Chi; D S Hoon
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

6.  Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Authors:  Donald L Morton; Eddy C Hsueh; Richard Essner; Leland J Foshag; Steven J O'Day; Anton Bilchik; Rishab K Gupta; Dave S B Hoon; Mepur Ravindranath; J Anne Nizze; Guy Gammon; Leslie A Wanek; He-Jing Wang; Robert M Elashoff
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

7.  Expression of beta-human chorionic gonadotropin genes in renal cell cancer and benign renal disease tissues.

Authors:  Yongguang Jiang; Fuqing Zeng; Chuanguo Xiao; Junmin Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.